Key Takeaways
- Sarepta Therapeutics said a patient taking its treatment for Duchenne muscular dystrophy has died from acute liver failure.
- The pharmaceutical firm said that “acute liver injury is a known possible side effect of Elevidys.”
- Sarepta shares sank more than 20% on the news.
Sarepta Therapeutics (SRPT) reported that a patient with Duchenne muscular dystrophy taking its Elevidys treatment died of acute liver failure (ALF). Shares plunged more than 20% on the news.
The pharmaceutical firm noted that “acute liver injury is a known possible side effect of Elevidys” and other similar gene therapies, although this was the first time a death had been reported of anyone taking the drug.
Sarepta explained that the patient had recently suffered from a cytomegalovirus (CMV) infection, “which was identified by the treating physician as a possible contributing factor.”
Sarepta told Investopedia, “We are continuing to gather information and work with (the Food and Drug Administration), but it is our intention to update the prescribing information to appropriately represent this reported liver failure event and any additional monitoring requirements.”
Including today’s sharp declines, shares of Sarepta Therapeutics have lost more than 35% of their value in the last year.
UPDATE—This article has been updated with a Sarepta statement and the latest share price information.
TradingView
